Terns Pharmaceuticals, Inc. ROE

ROE of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2021 was -234.04% (a -929.93% decrease from previous year)
  • Annual ROE for 2020 was 28.2% (a -76.67% decrease from previous year)
  • Annual ROE for 2019 was 120.9% (a 287.38% increase from previous year)
  • Twelve month ROE ending March 31, 2022 was -29.87% (a -87.24% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -Infinity% year-over-year
Trailing ROE for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-29.87% -234.04% -74.52% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Terns Pharmaceuticals, Inc.

Most recent ROEof TERN including historical data for past 10 years.

Interactive Chart of ROE of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -234.04%
2020 28.2%
2019 120.9%
2018 31.21%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.